Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabel Graupera

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 24, 2021
Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral DiseaseOctavi Bassegoda, Pol Olivas, Laura Turco, et al.
Journal of Hepatology|June 1, 2024
Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLDRafael Paternostro, Wilhelmus J Kwanten, Benedikt Silvester Hofer, et al.
Nature Communications|February 10, 2025
Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosisRaquel A Martínez García de la Torre, Julia Vallverdú, Zhenqing Xu, et al.
BMC Public Health|May 22, 2023
Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countriesIsabel Graupera, Maja Thiele, Ann T Ma, et al.
BMC Public Health|July 19, 2022
LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countriesIsabel Graupera, Maja Thiele, Ann T Ma, et al.
JAMA|February 5, 2025
Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical TrialElisa Pose, César Jiménez, Giacomo Zaccherini, et al.
JHEP Reports : Innovation in Hepatology|December 11, 2024
Loss of <i>Cdkn1a</i> protects against MASLD alone or with alcohol intake by preserving lipid homeostasisArantza Lamas-Paz, Alejandro Hionides-Gutiérrez, Feifei Guo, et al.
Lancet (London, England)|December 5, 2021
The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortalityTom H Karlsen, Nick Sheron, Shira Zelber-Sagi, et al.
Lancet (London, England)|August 12, 2023
Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort studyMiquel Serra-Burriel, Adrià Juanola, Feliu Serra-Burriel, et al.
Lancet (London, England)|April 13, 2026
Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort studyIsabel Graupera, Maja Thiele, Laurent Castera, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 24, 2021
Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral DiseaseOctavi Bassegoda, Pol Olivas, Laura Turco, et al.
Journal of Hepatology|June 1, 2024
Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLDRafael Paternostro, Wilhelmus J Kwanten, Benedikt Silvester Hofer, et al.
Nature Communications|February 10, 2025
Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosisRaquel A Martínez García de la Torre, Julia Vallverdú, Zhenqing Xu, et al.
BMC Public Health|May 22, 2023
Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countriesIsabel Graupera, Maja Thiele, Ann T Ma, et al.
BMC Public Health|July 19, 2022
LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countriesIsabel Graupera, Maja Thiele, Ann T Ma, et al.
JAMA|February 5, 2025
Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical TrialElisa Pose, César Jiménez, Giacomo Zaccherini, et al.
JHEP Reports : Innovation in Hepatology|December 11, 2024
Loss of <i>Cdkn1a</i> protects against MASLD alone or with alcohol intake by preserving lipid homeostasisArantza Lamas-Paz, Alejandro Hionides-Gutiérrez, Feifei Guo, et al.
Lancet (London, England)|December 5, 2021
The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortalityTom H Karlsen, Nick Sheron, Shira Zelber-Sagi, et al.
Lancet (London, England)|August 12, 2023
Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort studyMiquel Serra-Burriel, Adrià Juanola, Feliu Serra-Burriel, et al.
Lancet (London, England)|April 13, 2026
Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort studyIsabel Graupera, Maja Thiele, Laurent Castera, et al.
Pageof 11